Loading
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
Previous close
$1.26
+$0.01 · +0.80%
Regular session · ET · Market data may be delayed.
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
Day range
Current $1.26
52-week range
Current $1.26
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
81
Deep Value
Sentiment
55
Mixed
Risk
85
Extreme Risk
Momentum
22
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
Day range
Current $1.26
52-week range
Current $1.26
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 72.95M USD | 41.51M USD | 755K USD | 19.17M USD | 30.35M USD |
| Cost of goods sold | 9.8M USD | 9.18M USD | 7.42M USD | 8.48M USD | 1.84M USD |
| Gross profit | 63.15M USD | 32.32M USD | −6.66M USD | 10.69M USD | 28.5M USD |
| Research and development | 93.52M USD | 90.54M USD | 87.65M USD | 97.5M USD | 117.84M USD |
| Selling, general, and administrative | 8.6M USD | 8.42M USD | 8.12M USD | 8.9M USD | 22.88M USD |
| Operating expenses | 96.23M USD | 91.88M USD | 90.64M USD | 100.35M USD | 131.98M USD |
| Interest income | 9.5M USD | 11.28M USD | 3.61M USD | 1.12M USD | 719K USD |
| Interest expense | 8.11M USD | 7.45M USD | 5.31M USD | 3.79M USD | 4.17M USD |
| Depreciation and amortization | 20.06M USD | 19.85M USD | 18.52M USD | 18.44M USD | 14.16M USD |
| Operating income | −33.08M USD | −59.55M USD | −97.3M USD | −89.67M USD | −103.48M USD |
| Net income | −67.59M USD | −36.76M USD | −101.06M USD | −106.14M USD | −114.2M USD |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$2.15
70.63% upsideFunds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
